Chun Y.

In Prism, we are working on therapeutic antibody development for drug delivery target on solid tumors, including preclinical antibody discovery, development, antibody engineering/humanization, top candidate affinity maturation, characterization, preclinical assay development, drug pharmacological studies, drug potency assays for translational research, etc. • Developing mAb hybridoma for drug delivery targets; • Antibody engineering and humanization: these include cloning mAb genes from hybridoma, expressing recombinant mAbs in ExpiCHO system, lead recombinant mAb humanization/optimization for minimizing immunogenicity with protein modeling software, and Fc engineering for improving or silencing effector functions and drug conjugation functions, improving drug stability, et al; • Naïve and immunized phage-display scFv and Fab library construction and panning/screening, in vitro affinity maturation; • Biophysical characterization for recombinant mAb and humanized lead mAbs: these include size-exclusion chromatography(SEC) with several detectors (diode array UV/visible, Multiple Angle Light Scattering (MALS), Quasi-Elastic Light Scattering (QELS), and refractive index (RI)); reversed phase (RP), hydrophobic interaction chromatography (HIC), and ion-exchange chromatography; the biophysical property of binding affinity evaluation by one site binding ELISA and Biacore label-free real time platform; the specificity confirmation with ELISA against recombinant target protein and WB against both recombinant protein and cell lysates, et al. • Developing preclinical in vitro/in vivo assays to characterize the Ab potency; PK/PD studies, toxicity study/drug bio-distribution, et al; • Managing the communication with CMOs for protocol transfer and cGMP production of therapeutic antibody; • Working closely with chemist group for ADC; • Working closely with in vivo biology group to characterize the ADC potency in vivo;

My roles and responsibilities in EMD Millipore/MilliporeSigma are focusing on following areas: • Assay development and validation for all in house/OEM/licensed Abs, including cell based assay, immune-based assay, multiplex assay, IVD assay, CHIP assay, etc; • Antibody validations for all in house/OEM/licensed Abs. Extensive experience in Ab validation models and process, including ELISA, WB, IP, ICC, IHC, FLOW, etc.; • Building and developing antibody target validation system in Blot/lysate Library Core, consistently supplying quality-controlled stimulated cells, lysates, PVDF blots for RD, QC, MF validations. • New polyclonal and monoclonal antibody development: antigen design; animal immunization; serum/supe screening using different cellular models with different applications; hybridoma cell fusion/cloning; antibody purifications; et al; • New antibody development technologies, including antibody engineering and developing recombinant rabbit monoclonal antibodies in CHO Cells using UCOE system; new cell assay technology evaluations, et al; • Serving as supervisory role for QC department for bioscience product quality control and validation; • Working closely with cross-functional teams to achieve the pre-defined goals.

Functional analyses of protein degradation in immune system.